TargetMol

Xanthine amine congener trihydrochloride

Product Code:
 
TAR-T23535L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T23535L-1mg1mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23535L-5mg5mg£262.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23535L-10mg10mg£349.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23535L-25mg25mg£541.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23535L-50mg50mg£744.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23535L-100mg100mg£1,002.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Xanthine amine congener trihydrochloride is a potent adenosine antagonist that reverses the reduction in urine flow, sodium excretion and heart rate produced by the adenosine agonist, N6-cyclohexyladenosine.
CAS:
2459963-12-1
Formula:
C21H31Cl3N6O4
Molecular Weight:
537.87
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9785
SMILES:
Cl.Cl.Cl.CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccc(OCC(=O)NCCN)cc1
Target:
Adenosine Receptor

References

1. Barone S, Churchill PC, Jacobson KA. Adenosine receptor prodrugs: towards kidney-selective dialkylxanthines. J Pharmacol Exp Ther. 1989 Jul;250(1):79-85.